TSE:ATE Antibe Therapeutics (ATE) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free ATE Stock Alerts C$0.30 0.00 (0.00%) (As of 04/23/2024 ET) Add Compare Share Share Today's RangeC$0.30▼C$0.3050-Day RangeC$0.17▼C$1.0352-Week RangeC$0.15▼C$1.23VolumeN/AAverage Volume135,475 shsMarket CapitalizationC$15.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Get Antibe Therapeutics alerts: Email Address Ad Stansberry ResearchSee this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) Click here to see it. About Antibe Therapeutics Stock (TSE:ATE)Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Read More ATE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATE Stock News HeadlinesApril 9, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - ATEMarch 4, 2024 | finance.yahoo.comAntibe Announces Unfavorable Decision in Arbitration With Nuance PharmaApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 1, 2024 | finance.yahoo.comAntibe Extends Early Warrant Exercise Incentive ProgramDecember 31, 2023 | morningstar.comAntibe Therapeutics Inc ATEDecember 29, 2023 | finance.yahoo.comAntibe Announces Early Warrant Exercise Incentive ProgramNovember 13, 2023 | finance.yahoo.comAntibe Reports Q2 2024 Interim Financial and Operating ResultsNovember 8, 2023 | theglobeandmail.comAntibe Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (ATE)April 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.November 6, 2023 | baystreet.caHercules at 52-Week High on Barrick HookupNovember 1, 2023 | baystreet.caAntibe at 52-Week High on NewsNovember 1, 2023 | finance.yahoo.comAntibe Completes First Clinical Study of Otenaproxesul’s New FormulationOctober 18, 2023 | benzinga.comAntibe Initiates First Clinical Study of Otenaproxesul's New FormulationSeptember 28, 2023 | ca.finance.yahoo.comStocks in play: Antibe Therapeutics Inc.September 28, 2023 | finance.yahoo.comAntibe Receives Approval to Initiate PK/PD Study of OtenaproxesulSeptember 6, 2023 | investing.comAntibe Therapeutics Inc. (ATE)August 21, 2023 | finance.yahoo.comToronto Stock Exchange, Antibe Therapeutics Inc., View From The C-SuiteAugust 21, 2023 | finance.yahoo.comToronto Stock Exchange, Antibe Therapeutics Inc., View From The C-SuiteAugust 17, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc down on Wednesday (ATE)June 30, 2023 | finance.yahoo.comAntibe Therapeutics Inc.'s (TSE:ATE) Path To ProfitabilityJune 23, 2023 | baystreet.caLast Week of June Looks EventfulJune 16, 2023 | travel.usnews.comBest Times To Visit AntibesJune 13, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc up on Monday (ATE)June 3, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc down on Friday (ATE)May 19, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc up on Thursday (ATE)April 28, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc flat on Thursday (ATE)April 25, 2023 | finance.yahoo.comAntibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials SummitSee More Headlines Receive ATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today4/25/2024Next Earnings (Estimated)7/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:ATE CUSIPN/A CIKN/A Webwww.antibethera.com Phone+1-905-5705103FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.35) Trailing P/E RatioN/A Forward P/E Ratio0.56 P/E GrowthN/ANet IncomeC$-18,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.72% Return on Assets-19.13% Debt Debt-to-Equity Ratio0.29 Current Ratio10.06 Quick Ratio9.58 Sales & Book Value Annual SalesC$9.71 million Price / Sales1.60 Cash FlowC$0.48 per share Price / Cash Flow0.61 Book ValueC$0.49 per share Price / Book0.60Miscellaneous Outstanding Shares52,670,000Free FloatN/AMarket CapC$15.54 million OptionableNot Optionable Beta0.12 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Daniel Marcel Legault J.D. (Age 66)L.L.B., President, CEO, Secretary & Director Comp: $744.67kMr. Alain Wilson M.B.A.MBA, Chief Financial OfficerMr. Scott Curtis C.F.A.M.Eng, Chief Operating OfficerDr. David James Vaughan Ph.D. (Age 74)Chief Development Officer Comp: $406.58kDr. Joseph Stauffer D.O. (Age 58)M.B.A., Chief Medical Officer Comp: $1.11MDr. Ana StegicExecutive Director of Clinical OperationsMs. Christina Cameron B.B.A.Vice President of Investor RelationsMr. Philip SternVice President of CommunicationsMore ExecutivesKey CompetitorsNeptune Wellness SolutionsTSE:NEPTResverlogixTSE:RVXSirona BiochemCVE:SBMReunion NeuroscienceTSE:REUNKane BiotechCVE:KNEView All CompetitorsInsidersDaniel Marcel LegaultBought 20,000 shares on 3/7/2024Total: C$10,000.00 ($0.50/share)Joseph StaufferBought 24,000 shares on 3/6/2024Total: C$9,600.00 ($0.40/share)View All Insider Transactions ATE Stock Analysis - Frequently Asked Questions Should I buy or sell Antibe Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATE, but not buy additional shares or sell existing shares. View ATE analyst ratings or view top-rated stocks. How have ATE shares performed in 2024? Antibe Therapeutics' stock was trading at C$0.93 on January 1st, 2024. Since then, ATE stock has decreased by 68.3% and is now trading at C$0.30. View the best growth stocks for 2024 here. When is Antibe Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 4th 2024. View our ATE earnings forecast. How were Antibe Therapeutics' earnings last quarter? Antibe Therapeutics Inc. (TSE:ATE) posted its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.04. Is Antibe Therapeutics a good dividend stock? Antibe Therapeutics (TSE:ATE) pays an annual dividend of C$0.05 per share and currently has a dividend yield of 0.00%. How do I buy shares of Antibe Therapeutics? Shares of ATE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:ATE) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmith“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.